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A B S T R A C T
The S100 family of proteins contains 25 known members that share a high degree of sequence and structural
similarity. However, only a limited number of family members have been characterized in depth, and the roles of
other members are likely undervalued. Their importance should not be underestimated however, as S100 family
members function to regulate a diverse array of cellular processes including proliferation, differentiation, inflam-
mation, migration and/or invasion, apoptosis, Ca2+ homeostasis, and energy metabolism. Here we detail S100
target protein interactions that underpin the mechanistic basis to their function, and discuss potential interven-
tion strategies targeting S100 proteins in both preclinical and clinical situations.
1. Introduction
Ca2+ can function as a second messenger involved in the control
of an array of cellular processes ranging from muscle contraction to
cell differentiation or cell death [1]. Ca2+ signalling and intracellular
Ca2+ levels are regulated by several Ca2+ transporters and membrane
channels. Importantly, Ca2+-binding proteins share a common ancestor,
and therefore the ability to regulate intracellular Ca2+ levels and many
Ca2+-signalling pathways [2]. These Ca2+ mediator proteins are charac-
terized by an EF-hand Ca2+-binding motif which transmits Ca2+ signals
by binding to, and thereby regulating, specific target proteins in their
Ca2+-bound conformation [3].
Within the EF-hand superfamily the S100 proteins form the largest
subfamily, with 25 currently known members comprising a set of
non-ubiquitous Ca2+-modulated proteins implicated in multiple intra-
cellular and/or extracellular regulatory activities [4]. Although S100
proteins are expressed exclusively in vertebrates, each has a unique ex-
pression and distribution profile amongst different tissues and cell types.
The key characteristics of each member are summarised in Table 1.
Due to the diverse range of cellular functions undertaken by S100
proteins [5] some family members have been given more than one
name. These include S100A4, which is also known as calvasculin,
S100A6, which is also known as calcyclin, and the dimer formed by
S100A8/A9, which is known as calprotectin (Table 1). Additionally,
calgranulins comprise a group of S100 proteins including S100A8 (cal-
granulin A), S100A9 (calgranulin B) and S100A12 (calgranulin C),
which act as sensors of intracellular Ca2+ levels.
Various Ca2+-binding proteins such as calmodulin or troponin-C
only act at the intracellular level. However, other S100 proteins
act both as intracellular mediators and as extracellular signalling pro-
teins, being thereby able to regulate activities of target cells in either a
paracrine or an autocrine manner [5].
2. S100 protein structure, expression, and function
2.1. Molecular structure
The S100s constitute a family of proteins where each protein is en-
coded by an individual gene [6]. Of the 25 human S100 genes, 19
(group A S100 proteins) are located within chromosome 1q21. Other
members (S100A11P, S100B, S100G, S100P and S100Z) map to differ-
ent regions [6]. Every member of the S100 protein family has a sim-
ilar molecular mass of 10–12 KDa, and they each share 25–65% sim-
ilarity in their amino acid sequence. They exist as anti-parallel homo-
and heterodimers, with each monomer consisting of two helix-loop-he-
lix EF-hands (EF-1 and EF-2) connected by a hinge region and flanked
by conserved hydrophobic residues at the C- and N-terminal ends [7].
In the last 15 years, 3D structures of S100 proteins have been re-
vealed in three different forms: bound to Ca2+, bound to its target
protein, or in its apo (Ca2+-free) form. [8,9]. These studies have re-
vealed that upon Ca2+ binding, the S100 proteins experience a con-
formational change that allows interaction with target proteins. Fur-
thermore, each S100 protein presents a dimeric form, in a symmetric
shape. Each monomer contains two EF-hand motifs, with the N-termi-
nal EF-hand comprising helix I, Ca2+-binding site I and helix II, and the
C-terminal EF-hand comprising helix III, Ca2+-binding site II and he-
lix IV. Both EF-hand motifs are separated by a flexible hinge region, or
linker region [10]. Ca2+ binding to site I results in changes to the back-
bone conformation, the protein thereby acquiring a ‘Ca2+-ready’ state.
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Table 1
S100 proteins: cell/tissue expression, function, interacting partners, and associated disease pathologies.
S100 protein
Other
names Expression Function Interactions
Associated
pathologies Regulation Refs
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– [221]
This involves a ~40° rotation of helix III to a more open structure that
exposes a broad hydrophobic region including residues from helices III
and IV in the C-terminal EF-hand and hinge region. This regulates pro-
tein activity by enabling the respective S100 protein to interact with
many different target proteins including receptors and other S100 mem-
bers [3,11].
Certain S100 members have been described to bind to the same tar-
get molecules. For instance, S100A1, S100A6 and S100B interact with
annexin A6 [12], while S100A1, S100A2, S100A4 and S100B bind to
the tumour suppressor gene p53 [13,14]. This could be predictable
given the substantial sequence similarities between most of the S100
proteins. However, there is a subtle level of discrimination that pre-
vents arbitrary interaction of targets with any S100 protein. Struc-
tural studies of S100-target complexes have shown that S100 family
members use different mechanisms for target recognition despite the
similar conformational change induced by Ca2+ binding in all S100
family members [15–18]. Moreover, the region exposed upon Ca2+
binding comprises the most variable portions of the S100 sequences
(hinge and C-terminal regions), which is enough to discriminate against
different target proteins [10]. The distribution of hydrophobic and
charged residues, together with differences in surface configurations,
contribute to the specific target binding patterns described amongst
S100 family members [18,19].
2.2. Expression
Members of the S100 gene family show different patterns of both
cell- and tissue-specific expression (Table 1). Moreover, expression of
S100 proteins is carefully regulated in order to ensure the maintenance
of immune homeostasis [20]. Calprotectin (S100A8/A9), for example,
is constitutively expressed in certain immune cells including monocytes,
neutrophils, and dendritic cells [21]. However, upon activation, it is
also expressed in fibroblasts [22] or mature macrophages [23], amongst
other types of cells. In addition, epigenetic mechanisms also play a vital
role in regulating S100 gene expression, with methylation of DNA CpG
islands being a common method of transcriptional repression. Accord-
ingly, DNA hypomethylation has been reported to significantly induce












L.L. Gonzalez et al. BBA - Molecular Cell Research xxx (xxxx) xxx-xxx
2.3. Function
S100 proteins have been implicated in the control of a wide number
of intracellular and/or extracellular functions, including regulation of
cell apoptosis, proliferation, differentiation, migration/invasion, energy
metabolism, Ca2+ homeostasis, protein phosphorylation and inflamma-
tion in different cell types [5]. Some of their key regulatory functions
are detailed below.
2.3.1. S100s as damage associated molecular pattern (DAMP) molecules
DAMPs play a key role in the pathogenesis of many inflamma-
tory diseases, including rheumatoid arthritis (RA), osteoarthritis (OA)
and atherosclerosis. After cell damage/stress or activation of immune
cells including neutrophils and macrophages, S100 proteins are released
to the extracellular space where they play a key role in the regula-
tion of several immune and inflammatory processes [26]. They can
act as DAMP molecules to activate both immune and endothelial cells
by binding to toll-like receptors (TLR)s and receptors for advanced-gly-
cation end products (RAGE) (Fig. 1).
For example, there is evidence showing that binding of calprotectin
S100A8/A9 to TLR4 triggers a signalling cascade that modulates
processes such as inflammation, cell proliferation, differentiation and tu-
mour development via nuclear factor κB (NF-κB) activation [27]. Fur-
thermore, S100A12 binding to RAGE has been shown to induce expres-
sion of intercellular adhesion molecule-1 (ICAM-1) and vascular cell ad-
hesion molecule-1 (VCAM-1) on endothelial cells, as well as increasing
NF-κB-induced expression of proinflammatory cytokines such as tumour
necrosis factor α (TNF-α) by other inflammatory cells [28]. As such,
S100A12 has an essential role in the mediation of inflammation and has
been described to increase atherosclerosis in vivo through interactions
with RAGE [29,30].
Importantly, S100A4, S100A8/9, S100A11 and S100A12 have been
found to be upregulated in the synovial tissue, synovial fluid, or serum
of patients with RA [31–33]. Expression of S100A8/A9 was elevated in
the synovium of a collagenase-induced OA mouse model [34], as well
as in patients with sepsis, correlating with severity of disease [35
Fig. 1. Extracellular S100s signalling. S100 proteins are released from inflammatory cells including fibroblasts, macrophages, lymphocytes and neutrophils in response to inflammation
and stress. They signal through a range of cell surface receptors to activate several inflammatory signalling pathways which ultimately activate transcription of proinflammatory factors
including TNF-α, IL-1β, IL-6 and IL-8, as well as other mechanisms that lead to ROS formation and apoptosis. S100B signal through FGFR to activate the PI3K/PKB pathway. Most S100s
signal through RAGE to activate the JAK/STAT, PI3K/PKB and ERK/NF-κB pathways. EGFR-mediated signalling can also activate the PI3K/PKB and ERK/NF-κB pathways. GPCR-mediated
signalling can also activate NF-κB although the mechanism involved in unknown. S100A10 signals through the 5-HT1B receptor to activate ILK and NF-κB, while CD36-mediated signalling
activates the JNK/AP1 pathway. Abbreviations: 5-HT1B5-hydroxytriptamine 1B serotonin receptor; AP1 activator protein 1; CD36 cluster of differentiation 36; EGFR epidermal growth
factor receptor; ERK extracellular signalling-related kinase; FGFR fibroblast growth factor receptor; GPCR G protein coupled receptor; IL interleukin; ILK integrin-linked protein kinase; JAK
Janus kinase; JNK c-Jun N-terminal kinase; NF-κB nuclear factor κB; PI3K phosphatidyl inositol 3 phosphate; PKB protein kinase B; RAGE receptor for advanced glycation end products;
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]. S100A12 levels were also found to be significantly increased in the
synovial fluid of patients with OA when compared to healthy controls
[36].
DAMPs also play a role in the pathogenesis of neurodegenerative dis-
eases. S100B serum levels have been found to be closely associated to
the severity of diseases such as Alzheimer's [37] and Parkinson's [38]. In
addition, S100A10, which is also known as p11, increases expression of
the 5-hydroxytryptamine 1B serotonin receptor (5-HT1B) in HeLa cells
and brain tissue, and interestingly its expression has been shown to be
decreased in rodent models of depression [39].
2.3.2. S100s in immune cell migration, invasion and differentiation
Macrophages play a vital role in tumour development and metastasis
through several mechanisms including regulation of local inflammation,
inhibition of anti-tumour immunological processes and stimulation of
angiogenesis [40]. Macrophages are recruited by various chemoattrac-
tant molecules including chemokine ligands (CCL) 3–8 and macrophage
inflammatory protein 1 alpha (MIP-1α) [41]. Importantly, increasing
evidence show that several S100 proteins also contribute to leukocyte
migration. For instance, as well as inducing pro-inflammatory cytokine
production in macrophages through the activation of the NF-κB and p38
mitogen activated protein kinase (MAPK) pathways [42], S100A8/A9
has been seen to mediate immune cell migration [43]; S100A12 has
been shown to induce the production of pro-inflammatory cytokines in-
terleukin (IL) -6 and -8 through RAGE-dependent NF-κB activation, re-
sulting in the recruitment of monocytes [44,45]; S100A10 has been re-
ported to recruit macrophages to tumour sites [46]; whereas S100A8/
S100A9 have been shown to signal through RAGE to mediate the effect
of TNF-α on the differentiation of myeloid-derived suppressor cells [47].
3. Targeting S100 proteins in disease
3.1. S100s as biomarkers for disease
Since a number of S100 proteins can be identified in body fluids,
they may be used as biomarkers to detect a specific disease, where their
increased expression levels are indicative of pathological conditions
[48]. As such, S100A4 has recently been reported as a novel biomarker
and an important regulator of glioma stem cells, with its increased ex-
pression contributing to the appearance of a metastatic phenotype [49],
as well as having been described as a marker for lupus nephritis activ-
ity, a determinant factor for the onset of the complex inflammatory au-
toimmune disease lupus erythematosus [50]; increased serum levels of
S100A6 have been reported in patients with gastric cancer [51]; S100A7
levels have been found to be increased in cerebrospinal fluid and brain
of patients with Alzheimer's disease [52]; blood levels of S100A12 are
increased in patients with diabetes [30] and it has also been used as
a biomarker for detection of other inflammatory disease such as sys-
temic-onset juvenile idiopathic arthritis [53]; augmented serum levels of
S100A8/A9 have been seen in individuals with obesity [54] and in pa-
tients with coronary artery diseases [55]. Importantly, S100A8/A9 has
also proven to be a useful biomarker for disease activity in the manage-
ment of inflammatory bowel diseases such as Crohn's disease [56], and
faecal S100A8/A9 detection can be used to differentiate inflammatory
bowel disease from irritable bowel syndrome [57]. Finally, recent evi-
dence shows that S100B can be used as a monitoring and prediction tool
for management of traumatic brain injury [58], while its overexpression
has also been associated with certain genetic disorders such as Down
syndrome [59] and even to certain mood disorders as a consequence of
glial pathology [60].
3.2. S100s as therapeutic targets
An increasing number of studies suggest that S100 proteins could be
used as potential therapeutic targets to treat a variety of diseases. S100
proteins, particularly calgranulins (S100A8, A9 and A12), play a major
role in the mediation of the immune responses characteristic of a series
of diseases, including inflammatory arthritis, atherosclerosis and micro-
bial infections [61], as well as joint inflammation and cartilage degra-
dation in patients with RA [62]. Furthermore S100A7 has been found
to be abundantly expressed in psoriatic lesions or in serum from psori-
atic patients [63] as well as in atomic dermatitis skin lesions, induced
by pro-inflammatory factors such as TNF-α, IL-17 and IL-22 [64].
Several S100 proteins bind to TLR4 [27,33,65] and RAGE [66] (Fig.
1). Amongst them, S100A8/S100A9, whose levels are found to be ele-
vated in the serum of patients suffering from rheumatoid arthritis and
other inflammatory conditions [62], elicits most of its effects via these
receptors [27]. Importantly, the heterodimeric form of S100A8/S100A9
can bind TLR4, whereas high extracellular Ca2+ concentrations induce
the formation of S100A8/S100A9 tetramers [67], preventing its interac-
tion with TLR4, thus providing an autoinhibitory mechanism for modu-
lating S100A8/9 biological activity [68].
Substantial evidence shows that tissue and serum levels of many
S100 proteins correlate with disease severity during tissue or local in-
flammation [5,68]. In addition, we have seen how extracellular S100
proteins can behave as DAMPs, triggering proinflammatory responses
and inducing autoimmune conditions and inflammatory disorders
[5,26,69]. Function-blocking antibodies directed towards receptors and
ligands have been widely used as therapeutic agents for the treat-
ment of numerous pathologies including cancers and in immune disor-
ders [71–74]. Given the extensive evidence indicating that extracellu-
lar S100 proteins mediate inflammatory responses in many pathologi-
cal conditions mostly through cell receptor signalling [62,65], the use
of S100 function-blocking antibodies might therefore provide an effec-
tive therapeutic strategy to treat these conditions. Some examples of
S100-neutralised activity in various diseases are described in further de-
tail below. In addition, anti-allergic drugs have been reported to bind to
S100A12, blocking downstream RAGE signalling and subsequent NF-κB
activation [75].
It has been well established that elevated extracellular S100A8/
S100A9 levels are closely linked to inflammatory and autoimmune dis-
eases, including rheumatoid arthritis [76], inflammatory bowel disease
[77], cystic fibrosis [78], diabetic nephropathy [79] and cardiovascu-
lar disease [80], amongst others. It has been seen that restriction of
S100A8/A9 activity with the use of small-molecule inhibitors or neu-
tralizing antibodies ameliorates pathological conditions in murine mod-
els [81]. For example, it has been seen that certain quinoline-3-car-
boxamides, compounds presently under study for the treatment of hu-
man autoimmune and inflammatory diseases, interact with S100A9 and
the S100A8/A9 complex, thus blocking their interaction with TLR4 or
RAGE and inhibiting TNF-α release in vivo [82]. Blockade of S100A8/
A9 has also recently been seen to reduce inflammatory processes in
murine models of arthritis [83]. Importantly, it has been suggested
that S100A8 would be a good target against obesity-induced chronic
inflammation [84]. Furthermore, it has been reported that increased
S100A8/A9 expression in the tumour microenvironment is associated
with the progression and aggressiveness of the disease [85,86]. In par-
ticular, it has been seen that extracellular S100A8/A9 plays a central
role in the recruitment of myeloid cells, thereby promoting the forma-
tion of a pre-metastatic niche and tumour growth [87,88]. It also pro-
motes the expression of serum amyloid 3, which recruits myeloid cells
to pre-metastatic spots [89], enabling the formation of a proinflamma-
tory environment that recruits circulating tumour cells. It has been seen











L.L. Gonzalez et al. BBA - Molecular Cell Research xxx (xxxx) xxx-xxx
of both myeloid cells and circulating tumour cells [89]. It has also
been reported that peptibodies (chimeric proteins consisting of a biolog-
ically active peptide and a fragment crystallizable (Fc) domain of im-
munoglobulin G (IgG)) [90] directed towards S100A8 and S100A9 re-
duce tumour-related complications in a range of cancer models [91].
Collectively, these studies underline the potential use of S100A8 and
S100A9 antibodies as therapeutic reagents, but also as diagnostic tools.
In addition, S100A4 and S100B have been shown to bind to p53 tu-
mour suppressor gene, inhibiting its phosphorylation and thereby lead-
ing to p53 down-regulation [14]. Inhibition of the S100B-p53 interac-
tion would therefore restore the anti-tumour function of p53.
In addition to direct interaction strategies to modulate S100 pro-
teins in disease, covalent modification has important implications for
the function of S100 proteins. For example, S100A7, S100A10, and
S100A11 activity is regulated through transglutaminase-dependent co-
valent modification [92]. In addition, several S100 proteins have been
seen to be S-nitrosylated, including S100B [93], S100A1 [94] and
S100A8/A9 [95]. Furthermore, the ability of S100A1 to act as a calcium
receptor is thought to be regulated by S–glutathionylation [96]. Other
covalent modifications such as sumoylation [97] and phosphorylation
[98] of several S100 proteins have also been described. Therefore, tar-
geting these modifications may also constitute an indirect way to modu-
late S100 structure or function, thus impacting upon disease pathophys-
iology and progression.
4. S100A4
Of all of the S100 family members, S100A4 is the most exten-
sively studied. As such it is worthy of consideration in its own right.
S100A4 has been given many names, including metastasin (MTS-1),
PEL-98, 18A2, 42A, P9KA, CAPL, calvasculin and fibroblast-specific pro-
tein (FSP-1) [99]. The human S100A4 gene maps to chromosome 1q21,
and comprises four exons that encode a protein containing 101 amino
acid residues [100]. It is ubiquitously expressed, and present both intra-
and extracellularly, with intracellular levels being high both in the cyto-
plasm and in the nucleus [101].
S100A4 plays a significant role in many physiological functions in-
cluding cell motility, adhesion, proliferation, invasion, and metastasis
[102]. Intracellular S100A4 binds to proteins of the cytoskeleton in-
cluding F-actin and non-muscle myosin heavy chains [103], both in-
volved in cellular stability and/or motility [104]. By contrast, extracel-
lular S100A4 regulates the expression of extracellular matrix (ECM)-re-
modelling enzymes such as MMPs, which are implicated in mediating
cellular migration in various tissues [105], and can signal through mem-
brane receptors to activate proinflammatory pathways [106].
4.1. S100A4 signalling
4.1.1. Extracellular S100A4
Under a range of pathological stimuli, a number of inflammatory
cells including lymphocytes, macrophages and neutrophils upregulate
expression and release of S100A4 into the extracellular space in the form
of plasma membrane-derived macrovesicles [107]. Amongst the ways
in which extracellular S100A4 potentially exerts its effects, it has been
described to signal through several cell-membrane receptors including
RAGE, epidermal growth factor receptor (EGFR), TLR4 and IL-10 recep-
tor (IL-10R) [5,108].
RAGE is a transmembrane receptor of the immunoglobulin superfam-
ily. Its expression is cell type- and developmental stage-specific: while
it is highly expressed during embryogenesis, its expression decreases
in adult life [109]. However, its expression has been seen to be in-
creased in pathogenic environments such as inflammatory conditions
[110]. For example, increased expression of RAGE and some of its lig-
ands has been found in atherosclerotic lesions from diabetic individuals
who died unexpectedly from cardiovascular problems [111]. Further
more, numerous studies reveal that RAGE expression is low in the hu-
man kidney in physiological conditions, but that its expression is in-
creased in kidney failure-related diseases, including diabetes [112].
As with other S100 family members, RAGE are well-established in-
teraction partners of S100A4 [113]. In addition to inducing smooth
muscle proliferation in atherosclerosis [113], it has been reported that
binding of extracellular S100A4 to these receptors increases the migra-
tory and invasive capabilities of colorectal cancer cells via activation of
MAPK/extracellular signal-regulated kinase (ERK) and NF-κB, as well as
hypoxia signalling through the hypoxia inducible transcription factor,
HIF-1α, upregulation [114] (Fig. 2).
Extracellular S100A4 signalling activates several major proinflam-
matory pathways, including the MAPKs p38, ERK and c-Jun N-terminal
kinases (JNK) [115]. This triggers leukocyte migration and recruitment
during immune responses, inducing a self-amplifying pro-inflammatory
cycle through the upregulation of various pro-inflammatory cytokines
(IL-1β, IL-6, and TNF-α) and other immune cell related factors, as well as
several well-established inflammation-associated S100 proteins includ-
ing S100A8 and S100A9, thereby enabling the development of an in-
flammatory milieu [106].
Extracellular S100A4 also triggers the activation of another key
proinflammatory transcription factor, namely NF-κB [108,116]. Im-
portantly, both NF-κB and MAPKs are main transcriptional regulators
of various MMPs [117], and could therefore mediate S100A4-induced
stimulation of cell migration and metastasis. The underlying mecha-
nisms of S100A4-mediated activation of MAPKs and NF-κB have not
been fully described. In chondrocytes, this process is dependent on the
interaction of S100A4 with RAGE [116], whereas in primary neurons
and endothelial cells, the activation of this signalling pathway appears
to be RAGE-independent [118]. It has been widely demonstrated that
extracellular S100A4 induces NF-κB activation in human cancer cell
lines through the classical NF-κB pathway [119,120] to promote cell
migration and metastasis. It has been recently proposed that S100A4
constitutes a link between cancer-related metastasis and inflammation
[107]. However, very little is known about the role of S100A4 in the ac-
tivation of the inflammatory processes mediated by NF-κB in many au-
toimmune diseases, fibrosis, and other disorders.
4.1.2. Intracellular S100A4 signalling
Intracellular S100A4 was firstly identified in tumour cells, and ac-
cordingly, extensive evidence shows that an upregulation in S100A4
intracellular levels correlates with increased tumour cell motility
[121,122]. Besides tumour cells, intracellular S100A4 is expressed in
normal cells and tissues, including fibroblasts and cells of the immune
system [123]. For instance, it has been seen to be expressed in astro-
cytes, where its levels increase after injury, inducing astrocyte migra-
tion and repair responses [121]. Importantly, a model of S100A4 (−/−)
mice shows impaired recruitment of macrophages to inflammation sites
in vivo, whereas macrophages derived from these mice showed defective
chemotaxis in vitro [123]. Overall, these findings indicate that intracel-
lular S100A4 plays a major role in conferring migratory capacity to cells,
mainly to non-metastatic tumour cells during an epithelial to mesenchy-
mal transition, as well as to cells of the immune system including lym-
phocytes, neutrophils and macrophages during the progress of the im-
mune response [124].
One of the mechanisms through which this intracellular S100A4 up-
regulation is thought to take place is through TGF-β-induced expression
[125]. Secretion of proinflammatory cytokines and other factors such
as TGF-β by activated immune cells and fibroblasts signal through the
SMAD2/SMAD3 pathway to induce expression of intracellular S100A4,
which is then able to interact with cytoskeleton–associated target mole-
cules such as acto-myosin filaments, tropomyosin or non-muscle myosin
heavy chain IIA (NMIIA) (Fig. 2). This interaction destabilises the
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Fig. 2. RAGE-mediated S100A4 signalling. Extracellular S100A4, released from fibroblasts, macrophages, lymphocytes, neutrophils, vascular cells, and other bone marrow derived cells,
signals through RAGE, leading to increased phosphorylation of MAPKs and subsequent activation of NF-κB, inducing expression of pro-inflammatory genes. On the other hand, TGF-β
secreted from immune cells induces intracellular expression of S100A4, which is then able to interact with a number of target molecules, including NMIIA, tropomyosin, p53, and actin,
to form complexes that facilitate the remodelling of microtubes and microfilaments to enhance cell motility and chemotaxis, as well as contributing to the infiltration of fibroblasts, im-
mune cells and vascular cells into the affected region. In addition, binding of intracellular S100A4 to p53 promotes cell proliferation and collagen expression via MAPK activation and
phosphorylation of ERK. Finally, extracellular S100A4 signalling through RAGE can also activate hypoxia signalling through upregulation of HIF-1α. Abbreviations: ERK extracellular sig-
nalling-related kinase; HIF-1α hypoxia inducible factor 1α; MAPK mitogen-activated protein kinases; NF-κB nuclear factor κB; NMIIA non-muscle myosin IIA; RAGE receptor for advanced
glycation end products; TGF-β transforming growth factor β.
timately resulting in enhanced migration [126]. In the case of fibrob-
lasts and immune cells, this enhanced migration allows subsequent in-
filtration into the affected regions, inducing the release of inflamma-
tory factors and thereby contributing to the aggravation of pathological
processes [127]. Additionally, intracellular S100A4 is also able to bind
to p53. This interaction inhibits p53 phosphorylation and subsequent ac-
tivation, thereby modulating transcription of cell cycle-regulating genes,
and consequently stimulating apoptosis [124]. Importantly, intracellu-
lar interactions of S100A4 with the mentioned cytoskeleton target mol-
ecules as well as with p53 are Ca2+-dependent, thus linking the cellular
functions of these proteins with changes in intracellular Ca2+ concen-
trations and consequently with the energetic status of the cells [124].
4.2. S100A4 in disease
4.2.1. S100A4 and cancer
In the last years, the number of cancer cases has increased world-
wide, making it the second leading cause of death behind cardiovas-
cular disease [128]. Environmental factors such as increased pollu
tion, together with unhealthy lifestyles including tobacco smoking, al-
cohol consumption, changing diet patterns and lack of exercise, as well
as increased life expectancy associated with better medical services,
have been considered responsible for this situation. There were 14.1
million new cancer cases and 8.2 million deaths attributable to cancer
worldwide in 2012 [128]. Prevention and treatment measures to re-
duce cancer incidence have been introduced, but little progress is being
made [129]. Consequently, most cancers continue to appear, grow, and
metastasize due to the lack of effective management strategies [128].
S100A4, together with many other proteins, have been seen to be
involved in the complex multi-step process of cancer metastasis at the
molecular level [124,130]. It has been well established that S100A4, se-
creted from both tumour and non-malignant cells, plays a key role in the
regulation of angiogenesis, cell migration and inflammation [131,132].
It was first shown to be associated with tumour metastasis in 1989
[133], and later, it was discovered that transfection of S100A4 could in-
tensify the tumorigenic potential and induce the metastatic phenotype
in vivo [134].
It was not until the year 2000 that S100A4 overexpression was
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tial. This was seen in a case of human breast cancer [135]. From this
date, S100A4 levels have been found to be increased in many types of
cancers and tumour microenvironments, including brain, breast, lung,
gastric, liver, pancreatic, colorectal and prostate cancers amongst oth-
ers, in addition to osteosarcoma, leukaemia and malignant melanoma,
always associated to poor prognosis [136–139]. Thus, S100A4 is now a
strong likely biomarker for cancer diagnosis and metastasis prediction.
Intracellular S100A4 expressed by cancer cells, as well as by fi-
broblasts and immune cells, interacts covalently with target molecules
such as actin, non-muscle myosin IIA and tropomyosin [140], all of
them associated with cell migration, metastasis and tumour cell spread
[104,123]. Intracellulas S100A4 has also been seen to interact with
p53, methionine aminopeptidase 2, and liprin-β1, although not all of
them have been confirmed in vivo [141].
As an extracellular protein, S100A4 released from tumour and/or
stromal cells can alter the tumour microenvironment by stimulating an-
giogenesis and attracting immune cells to the developing tumour lesions
[142], as well as by inducing release of several cytokines and growth
factors. Importantly, studies using breast adenocarcinoma and cervical
carcinoma cell lines [143] have shown that extracellular S100A4 can
signal through RAGE to induce nuclear translocation of intracellular
S100A4, which when in the nucleus may function as a transcription fac-
tor for various genes including those encoding adherence junction pro-
teins, and thereby regulating cell motility. Nuclear expression of S100A4
in tumour cells is therefore a substantial, independent indicator of poor
prognosis. This also connects extracellular S100 proteins with intracel-
lular responses [144].
S100A4 has been seen to induce and drive metastasis in many can-
cers, but experiments with transgenic mice have revealed that it is not
a tumour-initiating oncogene, as well as having suggested that S100A4
needs to couple with an oncogene in order to induce cancer [145]. The
proposed mechanism by which S100A4 promotes metastasis in many
cancer types is via epithelial-to-mesenchymal transition (EMT), a com-
plex molecular process involving a change in cell morphology and func-
tion in which cells acquire fibroblastic phenotype and stem cell features
[146]. Transforming growth factor β (TGF-β), a key triggering factor of
the EMT process, induces upregulation of S100A4 through the activation
of the SMAD pathway, decreasing expression of epithelial cell markers
and increasing expression of mesenchymal cell markers [147].
S100A4 was initially described to promote EMT through downregu-
lation of the cell-adhesion molecule E-cadherin [148]. Since then, other
mechanisms of S100A4-induced activation of EMT have been described
in different types of cancer. In colorectal cancer, S100A4-induced EMT
is mediated by TGF-β-induced activation of the phosphatidyl inositol 3
kinase (PI3K)/protein kinase B (PKB)/mammalian target of rapamycin
(mTOR)/ribosomal protein S6 kinase beta 1 (p70S6K) signalling path-
way [149]. In pancreatic cancer, it is mediated by the sonic hedge-
hog-gli1 (SHH-GLI1) signalling pathway [150]. In gallbladder cancer,
overexpression of c-Myc and MMP14 induces loss of E-cadherin expres-
sion and subsequent increase in S100A4 expression [151]. In prostate
cancer, NF-κB-dependent transcriptional activation of MMP9 induces
S100A4-mediated cell invasion and malignant phenotypes [152]. In os-
teosarcoma, S100A4-induced tumour invasion and metastasis is also me-
diated through the dysregulation of MMPs and the expression of tissue
inhibitors of metalloproteinases (TIMPs) [153], whereas in leukaemia,
preferentially expressed antigen of melanoma (PRAME) suppresses heat
shock protein HSP27 and S100A4 expression, inducing cell apoptosis
and inhibiting cell proliferation and tumorigenicity [154].
4.2.2. S100A4 and non-cancer pathologies
Even though S100A4 is best known in a disease context for its par-
ticipation in cancer progression and metastasis, an increase in S100A4
expression has also been associated with several non-tumour patho-
physiological processes including tissue fibrosis, inflammation, neuro-
protection and cardiovascular events [155]. Numerous studies indicate
that the S100A4-mediated EMT plays a crucial role in the appearance
and development of both tumour and non-tumour pathophysiologies.
The EMT process can be classified into three subtypes [156]: Type I
EMT (non-pathological tissue development) takes place during regular
organogenesis; type II EMT (pathological conditions) is related to wound
healing, tissue regeneration, and organ fibrosis; finally, type III EMT is
associated with neoplastic cells, which can migrate into surrounding tis-
sues and infiltrate at metastasis sites [157–159].
S100A4 controls tissue fibrosis associated with type II EMT through
several mechanisms. Epithelial cells that have undergone EMT express
S100A4, inducing the production of extracellular matrix components
and thereby initiating tissue fibrosis [160]. Moreover, TGF-β-induced
S100A4 expression induces secretion of fibronectin from fibroblasts,
contributing to the establishment of a pro-inflammatory niche [161].
Given its specific expression patterns, S100A4 expression is regularly
used to follow the development of tissue fibrosis [146]. Simultane-
ously, extracellular S100A4 secreted in response to inflammatory cy-
tokines signals through RAGE, promoting the recruitment and chemo-
taxis of macrophages, neutrophils, and leukocytes via the activation of
the MAPK and NF-κB pathways [108], thereby activating a positive
feedback-regulated pro-inflammatory cycle through the upregulation of
various pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, and
thus regulating inflammation and immune functions [162]. S100A4 is
also involved in angiogenesis, thus inducing its metastasis-promoting
mechanisms via interaction with annexin 2 and stimulation of MMP pro-
duction [105,163]. Interestingly, it has also been seen that silencing
S100A4 inhibits retinal neovascularization in a mouse model of oxy-
gen-induced ischaemic retinopathy, an inflammatory disease [164].
It has been described that certain members of the S100 protein
family display obesity-facilitating properties. For instance, S100B pro-
motes obesity by reducing insulin sensitivity [165], while overexpres-
sion of S100A16 can promote adipogenesis in 3T3-L1 preadipocytes
[166]. S100A4 expression has also been described to have a role in the
pathogenesis of a number of autoimmune diseases and other inflamma-
tory conditions including rheumatoid arthritis, systemic sclerosis, pso-
riasis [31], diabetes retinopathy [167] and inflammatory myopathies
[106]. Given that S100A4 white adipose tissue (WAT) expression has
been reported to associate positively with expression of genes involved
in inflammation and immune cell activation, as well as with those in-
volved in ECM formation, organization and migration [168], S100A4
may also have obesity-facilitating properties, given that obesity has been
described to be a state of low-grade chronic inflammation [169].
Adipokine secretion from WAT has been associated with WAT dys-
function and metabolic complications of obesity. The size of fat cells
might constitute a determinant factor for metabolic disease linked to
pathological WAT [170]. WAT can be made of a large number of small
fat cells (hyperplasia) or a small number of large fat cells (hypertrophy).
Hypertrophic WAT is closely related to insulin resistance (IR), risk of
type 2 diabetes (T2D) and other metabolic abnormalities [171]. The
correlation between S100A4 expression and fat cell size suggests that
S100A4 could constitute an indicator of WAT hypertrophy, which could
consequently explain its association with IR [168]. S100A4 could there-
fore be classified as a novel adipokine linked to a pathological adipose
phenotype, including adipocyte hypertrophy and increased expression
and secretion of proinflammatory factors [168].
The known association between S100A4 and cancer suggests that
perhaps it has a role in linking obesity/IR with cancer. It is known that
in cancer cells, WNT/β-catenin signalling increases S100A4 gene tran-
scription, leading to an increase in tumour progression and invasive-
ness [172]. Conversely, the inhibition of this pathway reduces S100A4
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tors known to be involved in regulating S100A4 expression in different
cancer cell types are C/EBPβ [174], c-Myb [175] and SHH [150].
While the mechanism of transcriptional regulation of S100A4 in dif-
ferent AT cells are yet to be fully elucidated, given the commonality be-
tween obesity/IR and WAT dysfunction to both T2D and certain types
of cancer, it is tempting to speculate involvement of S100A4 in both.
Indeed, the auto-inflammatory component of T2D is, in part, associated
with the excessive AT proliferation that causes hypoxia in AT [176].
Rapid AT expansion causes a reduction in oxygen availability, exposing
cells to hypoxia. This will result in activation of hypoxia inducible fac-
tor 1α (HIF-1α), a transcription factor that activates transcription of sev-
eral apoptosis-related genes, as well as other factors including S100A4.
Given that HIF-1α can also participate in the ROS response that results
from hyperglycaemia in diabetes, this may therefore represent a unify-
ing molecular mechanism in diabetes (Fig. 3).
4.3. S100A4 therapeutics
S100A4 has proven to be a valuable biomarker and therapeutic tar-
get for many types of cancer. As a biomarker, the identification of
S100A4 levels in tumour tissues or in body fluids could predict progno-
sis and metastasis of cancer patients in the early stages, whereas as a
target, the inhibition of S100A4 expression can reduce metastasis in vivo.
Several molecular targeting strategies for S100A4 have been developed
[177]. The use of these new techniques has made it possible to discover,
for instance, the exact atomic structure of the interaction between intra-
cellular S100A4 and NMIIA [101]. However, there is a currently unmet
clinical need to develop new therapeutic agents that function to modu-
late S100A4 expression and activity.
S100A4 expression is intimately associated with the proliferation,
aggressive phenotype and metastatic behaviour of numerous types of
human cancers, and as such is linked to poor outcome of cancer pa-
tients. Therefore, therapeutic strategies aimed at reducing S100A4 ex-
pression or biological activity might help reduce metastatic cancer, im-
prove prognosis and increase survival rates of patients with cancer, as
well as to combat non-tumour pathophysiology processes such as tis
sue fibrosis, inflammation, immune reaction, neuroprotection and car-
diovascular disease.
Strategies to decrease the S100A4-mediated metastatic action in-
clude inhibition of S100A4 expression using miRNA-, siRNA- or
shRNA-based knockdown of S100A4 with the use of neutralizing an-
tibodies, or with the use of specific small molecule inhibitors. It was
reported in 1996 that ribozyme-based knockdown of S100A4 success-
fully reduced the S100A4-mediated osteosarcoma metastatic phenotype
[178], and more recently that this effect is mediated by the repres-
sion of MM9 [179]. It has also recently been seen that shRNA-mediated
S100A4 knockdown reduces metastasis formation in colorectal cancer
in vivo [180], while siRNA-mediated S100A4 knockdown induces apop-
tosis and inhibits metastasis of anaplastic thyroid cancer cells in vitro
[181]. Moreover, miR-3189-3p mimics have been seen to intensify the
effects of S100A4 siRNA on the inhibition of proliferation and migration
of gastric cancer cells [182].
S100A4 neutralizing antibodies have been demonstrated to decrease
tumour metastasis and T-cell recruitment in murine models of breast
cancer [183] and pre-metastatic lungs [184], as well as to block the
growth of pancreatic tumours in immunocompromised mice [185].
Transcription of S100A4 is controlled by the β-catenin/TCF complex
[172], therefore strategies that promote β-catenin degradation and/or
block the establishment of the β-catenin/TCF complex such as the use
of calcimycin, niclosamide or sulindac will be able to inhibit S100A4
transcription [186–188]. In fact, it was reported that in vitro treatment
of colorectal cancer cells with niclosamide reduces S100A4 expression,
subsequently inhibiting tumour cell migration, invasion, proliferation
and colony formation [187].
5. Conclusions
Molecular characterisation of primary tumour lesions has been used
to identify and evaluate the risk in the development of tumour metas-
tasis and to predict prognosis and therapy responses in various types
of cancer. As a result, several S100 members, mainly S100A4 and
S100A8/9, have been identified as key players in the pathogenesis of
many types of cancer, as well as of several other disease conditions in
Fig. 3. Oxygen-dependent regulation of HIF-1α and induction of S100A4 transcription. In normoxic conditions, PHDs hydroxylate HIF-1α, priming it for poly-ubiquitination by VHL, which
leads to its proteasomal degradation. In situations of hypoxia however, PHDs are inactivated, therefore HIF-1α is stabilized and translocates to the nucleus, where it binds to HIF-1β and
other co-factors. Together, they bind to HRE in the promoter region of target genes including S100A4. Increased levels of S100A4 induce secretion of proinflammatory factors and cell
migration and invasion. In addition to hypoxia, other factors found to be upregulated in diabetes such as TGF-β, PKB, and ROS, can also activate HIF-1α even in nonhypoxic conditions.
Abbreviations: HIF-1α hypoxia inducible factor 1 alpha; HIF-1β hypoxia inducible factor 1 beta; HRE hypoxia responsive elements; PHDs prolyl hydroxylases; PKB protein kinase B; ROS
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cluding diabetes and other inflammatory diseases. Elucidating the mech-
anisms of action of S100 proteins in the pathophysiology of these dis-
eases may therefore lead to the development and application of novel,
more effective therapeutic approaches. Future research should therefore
focus on the validation of the S100 proteins as biomarkers in early dis-
ease detection and prognosis, and in the development of novel strategies
based around anti-S100 therapies.
Abbreviations
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FSP-1 Fibroblast specific protein 1
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HSP Heat shock protein
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MAPK Mitogen activated protein kinase
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MMP Matrix metalloproteinase
mTOR Mammalian target of rapamycin
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PKB Protein kinase B
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RA Rheumatoid arthritis
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ROS Reactive oxygen species
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TLR Toll-like receptor
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